Mild CMV reactivation was associated with beneficial effects, while severe cases required treatment, which increased the risk of toxicity and infections.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

Updated thresholds outperform those recommended by American Thyroid Association guidelines for patients with medullary thyroid cancer.

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Many young adult survivors of childhood hematologic cancer do not have comprehensive survivorship care summaries or believe they need one.

Researchers reviewed cases in which patients experienced severe skin toxicities in response to immunotherapy, and sought to identify the distinct natures of these toxicities.

Researchers conducted a population-based cohort study to estimate the prevalence of major thyroid cancer-associated syndromes.

SAD-CP, a home-based palliative care program, was shown to effectively meet the care needs of patients with advanced cancer, particularly in underserved areas.

HealthDay News — Slightly higher levels of cardiac biomarkers may predict an increased risk for incident cancer, according to a study published online in the July issue of JACC: Advances.

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Researchers sought to determine whether salvage high-dose chemotherapy plus ASCT would be effective for patients with relapsed/refractory MM.